First Solar Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, auditor ratification, executive compensation, and a shareholder proposal to lower the threshold for calling special meetings. Record financial results and strategic technology initiatives were highlighted. All board proposals passed, while the shareholder proposal did not.
-
Record Q1 revenue and margin expansion driven by strong U.S. and India sales, with CuRe technology rollout advancing and full-year guidance reaffirmed. Pending U.S. tariff decisions and India policy changes remain key uncertainties.
Fiscal Year 2025
-
Record 2025 sales and strong cash position were driven by U.S. capacity expansion and disciplined contracting. 2026 guidance projects stable production, robust margins with Section 45X credits, and continued technology investment amid ongoing trade and policy uncertainties.
-
Q3 saw record module sales and strong earnings, but contract terminations with BP and supply chain disruptions led to revised guidance and a lawsuit for damages. A new U.S. finishing facility and robust cash position support long-term growth amid evolving policy and market risks.
-
Q2 2025 saw strong module sales, record EPS, and improved gross margin, driven by U.S. manufacturing and favorable policy changes. Updated guidance reflects tariff impacts, with robust demand and a solid backlog supporting long-term growth.
-
The meeting covered director elections, auditor ratification, executive compensation, and a failed shareholder proposal to ease special meeting requirements. Record financial results, manufacturing expansion, and technology initiatives were highlighted, with all management proposals passing.
-
Q1 2025 results showed lower-than-expected EPS due to a higher mix of international sales and new U.S. tariffs, prompting reduced guidance for the year. Despite near-term headwinds from tariffs and policy uncertainty, long-term U.S. solar demand and domestic manufacturing expansion remain strong.
Fiscal Year 2024
-
Record 2024 sales and module shipments drove a 27% revenue increase and a 55% EPS gain year-over-year, despite discrete costs from warranty and logistics. 2025 guidance projects further growth, with EPS expected to rise 50% at the midpoint, though policy and trade uncertainties pose near-term risks.
-
Q3 saw record production and strong backlog, but results were impacted by a $50M Series 7 warranty charge and operational disruptions. Full-year guidance was revised lower for volume and revenue, but gross margin and EPS remain within prior ranges.
-
Q2 2024 saw strong financial and operational results, with $1B in net sales, 49% gross margin, and $3.25 EPS. The contracted backlog reached 75.9 GW, and U.S. manufacturing expansion remains on track. Full-year guidance is unchanged despite policy and market uncertainties.